These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22757653)

  • 1. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing.
    Ko SY; Oh HB; Park CW; Lee HC; Lee JE
    Clin Microbiol Infect; 2012 Oct; 18(10):E404-11. PubMed ID: 22757653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
    Yim HJ; Hussain M; Liu Y; Wong SN; Fung SK; Lok AS
    Hepatology; 2006 Sep; 44(3):703-12. PubMed ID: 16941700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
    Baldick CJ; Eggers BJ; Fang J; Levine SM; Pokornowski KA; Rose RE; Yu CF; Tenney DJ; Colonno RJ
    J Hepatol; 2008 Jun; 48(6):895-902. PubMed ID: 18362040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.
    Ayres A; Yuen L; Jackson KM; Manoharan S; Glass A; Maley M; Yoo W; Hong SP; Kim SO; Luciani F; Bowden DS; Bayliss J; Levy MT; Locarnini SA
    J Viral Hepat; 2014 Nov; 21(11):809-17. PubMed ID: 24329944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance.
    Lee GH; Inoue M; Toh JK; Chong RH; Aung MO; Koay ES; Lim SG
    Liver Int; 2013 Apr; 33(4):642-6. PubMed ID: 23346997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
    Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
    J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.
    Tadokoro K; Suzuki F; Kobayashi M; Yamaguchi T; Nagano M; Egashira T; Kumada H
    J Virol Methods; 2011 Jan; 171(1):67-73. PubMed ID: 20950650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method.
    Ciftci S; Keskin F; Cakiris A; Akyuz F; Pinarbasi B; Abaci N; Dincer E; Badur S; Kaymakoglu S; Ustek D
    Diagn Microbiol Infect Dis; 2014 May; 79(1):25-30. PubMed ID: 24630522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus mutations associated with antiviral therapy.
    Bartholomeusz A; Locarnini S
    J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
    Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
    Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
    Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
    Guo JJ; Li QL; Shi XF; Zhang DZ; Zeng AZ; Feng T; Huang AL
    Antiviral Res; 2009 Feb; 81(2):180-3. PubMed ID: 18948142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.